Clinical trial NCT01911039: Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Official title: A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Graft Versus Host Disease
Allogeneic Hematopoietic Cell Transplant Recipient
Keywords: GVHD
cGVHD
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2013-07-30
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or hematopoietic cell transplant from another person (allogeneic transplant). This study will determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor regulatory T cells and whether their cGVHD responds to the infusion.

Detailed description: PRIMARY OBJECTIVES:

Determine the safety and tolerability of donor T regulatory (Treg) cell infusions in subjects with steroid dependent/refractory chronic graft versus host disease.

SECONDARY OBJECTIVES:

1. Determine the quantitative blood Treg cell changes following the cell infusions
2. Determine clinical efficacy of donor Treg cells as failure-free survival (FFS) defined by the absence of a new immunosuppressive therapy added, non-relapse mortality, and recurrent malignancy at Day 180 after the first Treg infusion
3. In addition to FFS, the study will measure the change in:

   1. cGVHD symptom burden measured by the Lee cGVHD Symptom Scale by increase in \>7 points
   2. NIH organ-specific cGVHD scale
   3. The reduction in daily corticosteroid requirement of prednisone to \<=0.25 mg/kg-day at Day 180 after the first Treg infusion

Eligibility criteria: Inclusion Criteria:

* Steroid dependent/refractory cGVHD defined as:

  * Steroid dependent disease: Persistent cGVHD manifestations requiring a glucocorticoid dose \>= prednisone 0.25 mg/kg/day (0.5 mg/kg orally \[po\] every other day) for at least 12 weeks
  * Steroid refractory disease: Progressive cGVHD manifestations despite treatment with a glucocorticoid dose \>= prednisone 0.5 mg/kg/day (1 mg/kg po every other day) for at least 4 weeks
* Participants must be receiving systemic glucocorticoid therapy for cGVHD; all immunosuppressive therapy may include but not be limited to tacrolimus, sirolimus, CellCept, cyclosporine, and systemic corticosteroid must be at stable doses for 28 days prior to the first cell infusion
* Chronic GVHD manifestations that can be followed on physical or laboratory exam; these include but are not necessarily limited to:

  * Skin changes
  * Oral mucosa changes
  * Bronchiolitis obliterans
  * Ocular changes
* Karnofsky performance status \>= 60
* Serum creatinine =\< 2 mg/dL
* Absolute neutrophil count (ANC) \> 1 x 10\^9/L
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 20 x upper limit of normal (ULN) or
* Total bilirubin =\< 10 x ULN
* Allogeneic hematopoietic cell transplant recipient
* Transfusion independent
* Oxygen saturation during exertion is maintained at \>= 88% on room air
* Does not have clinically significant, symptomatic uncontrolled heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
* DONOR: Age \>= 18 to =\< 75 years old
* DONOR: Karnofsky performance status of \>= 70% defined by institutional standards
* DONOR: Must be the same sibling donor from whom the recipient's blood and marrow graft was collected for the original allogeneic transplant that is human leukocyte antigen (HLA) 7/8 or 8/8 matched at the HLA-A, B,C, DRB1
* DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-lymphotropic virus type I (HTLV 1) and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction positive (PCR+), or hepatitis C Ab or PCR+, Syphilis (Treponema) screen and HIV 1 and hepatitis C by nucleic acid testing (NAT) have been collected prior to apheresis
* DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis
* DONOR: Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate
* DONOR: Donor selection will be in compliance with 21 Code of Federal Regulations (CFR) 1271

Exclusion Criteria:

* Original transplant utilized an unrelated donor graft
* Uncontrolled infections that are not responsive to antimicrobial therapy
* Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
* Second malignancy except for skin cancer within the last 5 years
* Received any investigational agent =\< 28 days before Treg infusions
* Received filgrastim (GCSF) treatment within one month of enrollment
* Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within 3 months of enrollment
* DONOR: Evidence of active infection or viral hepatitis
* DONOR: HIV positive
* DONOR: Pregnant donor

Primary outcomes:
measure: The frequency of adverse events related to the donor Treg infusions (e.g., grade III-IV aGVHD by the modified Keystone criteria and grade 3 or higher infusional toxicities graded according to the CTCAE v. 4)
timeFrame: Up to day 180
Secondary outcomes:
measure: Change in absolute blood Treg levels
timeFrame: Baseline to day 42
measure: Improvement in Failure Free Survival (FFS) over cGVHD
timeFrame: At day 180
measure: Successful achievement of cGVHD partial response or Complete response by the NIH consensus criteria
timeFrame: Up to day 180
measure: The ability to reduce steroid requirements to <0.25 mg/kg-day
timeFrame: At day 180
measure: Change in >7 points on the Lee cGVHD Symptom scale relates to improvement in quality of life
timeFrame: Baseline to day 180
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University, School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Laura Johnston
role: PRINCIPAL_INVESTIGATOR
References: